Outlook Therapeutics OTLK
NASDAQ OTLK
$0.68 -0.01 (-1.45%)
At close: Aug 20, 2026 · 4:00 PM EDT

Outlook Therapeutics (OTLK) EBT Margin (2015 - 2025)

Outlook Therapeutics (OTLK) posted quarterly EBT Margin of 16175.93% for Q3 2025, up 1308.29% quarter-over-quarter from 1338.75% in Q2 2025.

Outlook Therapeutics (OTLK) EBT Margin (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has reported EBT Margin for 6 consecutive years, with 16175.93% the latest figure, recorded in Q3 2025.

  • In Q3 2025, EBT Margin changed N/A year-over-year to 16175.93%; the TTM figure through Sep 2025 stood at 1312.52% (changed N/A YoY), while the FY2025 annual figure was 4526.01%, changed N/A from the prior year.
  • EBT Margin grew to 16175.93% in Q3 2025 per OTLK's latest filing, from 1338.75% in the prior quarter.
  • Across five years, EBT Margin topped out at 16175.93% in Q3 2025 and bottomed at 1338.75% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn 41.75%
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 35.61%
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn 35.71%
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn -528.97%
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 18.33%
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn 13.77%
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn -2.67%
8 Royalty Pharma 26.98 Bn 26.14 Bn - 12.09%
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn -25.06%
10 Outlook Therapeutics 93.64 Mn 82.40 Mn -8,265.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 16,175.93%
Jun 30, 2025 -1,338.75%
Sep 30, 2019 -217.47%
Jun 30, 2019 -893.79%
Mar 31, 2019 -1,597.90%
Dec 31, 2018 -912.50%
Sep 30, 2018 -1,644.94%
Jun 30, 2018 -1,092.37%
Mar 31, 2018 -976.81%
Dec 31, 2017 -656.99%
Sep 30, 2017 -202.47%
Jun 30, 2017 -1,758.72%
Mar 31, 2017 -2,654.21%
Dec 31, 2016 -6,298.89%
Sep 30, 2016 -2,135.40%
Jun 30, 2016 -4,511.46%
Mar 31, 2016 -350.98%
Dec 31, 2015 -1,689.85%
Sep 30, 2015 -3,647.43%
Jun 30, 2015 -895.87%